Local and Systemic Immune Dysregulation Alters Glioma Growth in Hyperglycemic Mice
Open Access
- 3 February 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (11), 2740-2753
- https://doi.org/10.1158/1078-0432.CCR-19-2520
Abstract
Purpose: Unlike most cancers, no clear epidemiological correlation between diabetes (Db) and malignant glioma progression exists. Because hyperglycemia activates proinflammatory pathways through the receptor for advanced glycation endproducts (RAGE), we hypothesized that Db can also promote malignant glioma progression. Experimental Design: We compared the growth of two phenotypically diverse syngeneic glioma models in control and diabetic mice. Tumor growth and antitumor immune responses were evaluated in orthotopic and heterotopic models and correlated to RAGE and RAGE ligand expression. Results: Irrespective of tumor implantation site, growth of a "classical" glioma model, GL261, increased in hyperglycemic mice and was mediated by upregulation of RAGE and its ligand, HMGB1. However, growth of a "mesenchymal" glioma subtype, K-Luc, depended on tumor implantation site. Whereas heterotopic K-Luc tumors progressed rapidly in Db mice, intracranial K-Luc tumors grew slower. We further showed that hyperglycemia inhibited the innate antitumor inflammatory responses in both models. Although this contributed to the accelerated growth of heterotopic tumors, suppression of tumor inflammatory responses dampened the growth of orthotopic K-Luc gliomas. Conclusions: Hyperglycemia may enhance glioma growth through promotion of RAGE expression and suppression of antitumor immune responses. However, abrogation of the proinflammatory milieu in tumors may also dampen the growth of inflammatory glioma subtypes in the brains of diabetic mice. This dichotomy in glioma growth response to hyperglycemia may partly explain why conflicting epidemiological studies show both an increased risk and a protective effect of Db in patients with malignant gliomas.Other Versions
Funding Information
- Liam McGee Brain Tumor Fund
- Joan Traver Walsh Family Foundation
- Analytical Cytometry and Molecular Pathology Cores
- NCI
- NIH (P30CA033572)
This publication has 53 references indexed in Scilit:
- The Association Between IGF-I and Insulin ResistanceDiabetes Care, 2012
- S100B attenuates microglia activation in gliomas: Possible role of STAT3 pathwayGlia, 2010
- Association Between Serum IGF-1 and Diabetes Among U.S. AdultsDiabetes Care, 2010
- Hyperglycemia-Induced Reactive Oxygen Species Increase Expression of the Receptor for Advanced Glycation End Products (RAGE) and RAGE LigandsDiabetes, 2009
- Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes MellitusJAMA, 2008
- Diabetes and Risk of Non-Hodgkin's LymphomaDiabetes Care, 2008
- Impaired immune responses in streptozotocin-induced type I diabetes in mice. Involvement of high glucoseClinical and Experimental Immunology, 2008
- Diabetes‐induced decrease of adenosine kinase expression impairs the proliferation potential of diabetic rat T lymphocytesImmunology, 2006
- NK Cells and Type 1 DiabetesJournal of Immunology Research, 2006
- Insulin-like growth factors and neoplasiaNature Reviews Cancer, 2004